ABSTRACT
BACKGROUND: Parkinson's disease is a common neurodegenerative problem. Pramipexole (PPX) plays protective role in Parkinson's disease. Nevertheless, the mechanism of PPX in Parkinson's disease-like neuronal injury is largely uncertain. METHODS: 1-methyl-4-phenylpyridinium (MPP+)-stimulated neuronal cells and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice were used as the model of Parkinson's disease. MPP+-induced neuronal injury was assessed via cell viability, lactic dehydrogenase (LDH) release and apoptosis. microRNA-96 (miR-96) and BCL2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) abundances were examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) or Western blotting. Mitophagy was tested by Western blotting and immunofluorescence staining. MPTP-induced neuronal injury in mice was investigated via behavioral tests and TUNEL. RESULTS: PPX alleviated MPP+-induced neuronal injury via increasing cell viability and decreasing LDH release and apoptosis. PPX reversed MPP+-induced miR-96 expression and inhibition of mitophagy. miR-96 overexpression or BNIP3 interference weakened the suppressive role of PPX in MPP+-induced neuronal injury. miR-96 targeted BNIP3 to inhibit PTEN-induced putative kinase 1 (PINK1)/Parkin signals-mediated mitophagy. miR-96 overexpression promoted MPP+-induced neuronal injury via decreasing BNIP3. PPX weakened MPTP-induced neuronal injury in mice via regulating miR-96/BNIP3-mediated mitophagy. CONCLUSION: PPX mitigated neuronal injury in MPP+-induced cells and MPTP-induced mice by activating BNIP3-mediated mitophagy via directly decreasing miR-96.
Subject(s)
Antiparkinson Agents/administration & dosage , Membrane Proteins/metabolism , MicroRNAs/metabolism , Mitochondrial Proteins/metabolism , Mitophagy/drug effects , Parkinsonian Disorders/metabolism , Pramipexole/administration & dosage , Animals , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , Male , Mice , Mice, Inbred C57BL , MicroRNAs/antagonists & inhibitors , Mitophagy/physiology , Neurons/drug effects , Neurons/metabolism , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/drug therapyABSTRACT
Treatment of the 2,5-bis(2'-pyridyl)pyrrolato (PDP-) anion with {Ru(COD)Cl2}n in THF readily yielded [Ru(PDP)(COD)Cl] (1) in almost quantitative yield. Anion metathesis of 1 in organic solvent by NO3- and OTf- (OTf- = triflato) gave [Ru(PDP)(COD)(NO3)] (2) and [Ru(PDP)(COD)(OTf)] (3), and in aqueous solution by BF4- and PF6- afforded aqueous complexes [Ru(PDP)(COD)(H2O)](BF4) (4+·BF4-) and [Ru(PDP)(COD)(H2O)](PF6) (4+·PF6-), respectively. Treatment of 1 with PhICl2 in CH2Cl2 afforded 5 with halogenated pyrrole. These complexes exhibit similar structure, including one Ru(ii) atom, one 2,5-bis(2'-pyridyl)pyrrole and one monodentate anion or aqua ligand. Each Ru(ii) tightly binds to three adjacent coplanar sites of PDP- ligand to form a meridional configuration. Complex 1 with NaIO4 as the oxidant in EtOAc-CH3CN-H2O (ratio = 3 : 1 : 2) proved to be highly effective in the catalytic oxidation of olefins to carbonyl products.
